SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, the largest commercial communications array ever deployed in low Earth orbit, validating its direct-to-device 5G technology. While some traders are taking profits in a "sell the news" reaction, many in the community view this as a pivotal de-risking event, anticipating significant future growth and a potential short squeeze as the company moves towards commercial scalability.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending due to the FDA's historic approval of YARTEMLEA, its first and only therapy indicated for TA-TMA, a serious complication of stem cell transplantation, which includes a broad pediatric label. The community is highly optimistic, anticipating a significant short squeeze and potential for substantial price appreciation given the drug's unique position. Discussion is also focused on the prolonged trading halt and future buyout prospects with existing partners like Novo Nordisk.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as Apple CEO Tim Cook's recent stock purchase sparks significant community discussion, viewed by many as a strong vote of confidence in the company. While some dismiss the insider buy as insignificant, others believe it signals a potential turnaround for the sportswear giant, which has faced headwinds from China sales and tariff concerns.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending as Sanofi has announced an all-cash agreement to acquire the company, offering a significant premium for its leading hepatitis B vaccine and promising shingles pipeline. The community is actively celebrating the immediate gains for shareholders, though some express sentiment that the valuation is conservative, fueling speculation about potential competing bids. This acquisition highlights Sanofi's strategic expansion in adult vaccines and reflects the ongoing M&A activity within the biotech sector.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is a trending topic amidst surging demand for its critical optical solutions, including co-packaged optics and high-speed transceivers, essential for the rapidly expanding AI data center infrastructure. The community is actively discussing strong analyst upgrades and robust earnings guidance, with many speculating on the company's significant undervaluation and potential as an acquisition target.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd ($AFJK) is trending due to its extremely low float and high cost to borrow, sparking intense community discussion about a potential short squeeze and dramatic price swings. Many traders are comparing its parabolic moves to other recent volatile low-float runners, while a mixed sentiment persists regarding its speculative nature following a blank check merger with a Chinese company.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending due to the recent US FDA approval of AQVESME (mitapivat) for treating anemia in adults with alpha- or beta-thalassemia, marking it as the first and only oral medicine for this condition. The community is actively discussing the significant market opportunity and potential future valuations following this landmark regulatory catalyst.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is actively trending as investors voice deep frustration with management's perceived inaction to secure partnerships, especially for its combination flu/COVID vaccine, a sentiment exacerbated by a competitor's recent acquisition. The community debates whether leadership's prolonged silence signals advanced buyout discussions or a strategic misstep, particularly as potential regulatory scrutiny on mRNA vaccines could highlight Novavax's protein-based platform as a differentiated alternative.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is seeing significant buzz driven by recent regulatory tailwinds and concrete progress on its multi-year strategic overhaul, including its Banamex divestiture. This momentum has led to new highs, with many investors anticipating further upside within a strengthening financial sector, though community sentiment also reflects caution about potential overbought conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings...

Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $6.00 by Analysts at Citigroup

Citigroup reduced their price objective on Biomea Fusion from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday...

Biomea Fusion FY2025 EPS Estimate Lowered by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright lowered their FY2025 EPS estimates for Biomea Fusion in a research note issued on Wednesday, November 5th. HC Wainwright analyst J...

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Moderate Buy" by Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat.com reports. One...

Biomea Fusion (NASDAQ:BMEA) Given New $12.00 Price Target at D. Boral Capital

D. Boral Capital dropped their price target on shares of Biomea Fusion from $16.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday...

Shares of Biomea Fusion drew heightened attention from retail investors on Tuesday after the company disclosed a public offering of its common stock and warrants.&nbsp;The stock closed up 10.3% at $2.9 on Tuesday but dropped 24.8% to $2.18 in after-hours trading.The offer includes shares, pre-funded warrants in place of shares to certain investors and accompanying warrants for the purchase of shares.Biomea said it will also give the underwriters a 30-day option to buy up to 15% more shares and pre-funded warrants. Jefferies is the sole book running manager.The offering is being made under a shelf registration and is expected to close on or around June 20, subject to customary closing conditions.&nbsp;Biomea said the completion, size, and terms of the offering are subject to market conditions and are not guaranteed.The offering comes just days after Biomea Fusion reported updated data from its Phase I Covalent 103 trial of BMF-500 in relapsed or refractory acute leukemia.&nbsp;The study, presented at the European Hematology Association Congress, showed early signs of clinical benefit in heavily pretreated patients with FLT3 mutations.&nbsp;The company said it plans to conclude internal development of BMF-500 in oncology and is exploring strategic partnerships to advance the program.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user said the raise could bring in around $30 million and&nbsp;added that while the added dilution might pressure the stock short-term, the reduced risk could unlock further upside, predicting a return above $3 in the coming weeks.&nbsp;<stembedurl>https://stocktwits.com/hashbridges/message/618219066</stembedurl>Another user expressed disappointment at the timing of the offering, saying they anticipated it at a higher price and would now hold the stock through year-end.<stembedurl>https://stocktwits.com/aquira/message/618214880</stembedurl>The stock has declined 21.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead

The offering follows early clinical data from Biomea’s BMF-500 leukemia program, which showed encouraging responses in heavily pretreated patients. 

Equity

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

Shares of Biomea Fusion attracted significant retail attention on Tuesday after H.C. Wainwright reduced its price target for the stock to $18 from $40, while maintaining a ‘Buy’ rating.&nbsp;The&nbsp;reduction followed the company’s first-quarter earnings report, where Biomea unveiled a strategic shift to focus on its core diabetes and obesity programs.&nbsp;As part of its strategy, Biomea has implemented a cost-reduction initiative, which includes a workforce reduction of nearly 35% to reduce overall operating expenses and extend its cash runway into Q4 2025.The firm also removed type 1 diabetes from its projections and pushed the launch of icovamenib for type 2 diabetes to 2031 from the previously anticipated 2029.Biomea’s stock price declined by 16.5%, closing at $1.67 on May 6, 2025. However, it rebounded slightly in after-hours trading, increasing by 1.74% to $1.70.Retail sentiment surged on Stocktwits, where sentiment was ‘bearish’ views amid a 1,400% uptick in message volume.&nbsp;The sentiment seemed to reflect speculation about the company’s next moves and the market’s potential reactions.One user questioned the company’s decision to delay share dilution when the stock was priced at $4 earlier this year, suggesting that the current price of $1.60 might not align with Biomea’s broader plans, hinting that something was amiss.&nbsp;<stembedurl>https://stocktwits.com/NGEA/message/613687181</stembedurl>Meanwhile, another user speculated that Biomea's recent actions could indicate a “short trap” and accumulation of shares ahead of potential positive news.&nbsp;The user pointed out that despite concerns of running out of cash, Biomea had not raised funds through share sales but instead reduced its workforce to stretch its runway.<stembedurl>https://stocktwits.com/NGEA/message/613678729</stembedurl>In its Q1 update, interim CEO Mick Hitchcock highlighted the company’s efforts to prioritize high-value opportunities, extend its cash runway, and maintain its focus on icovamenib and BMF-650.&nbsp;Biomea also reported a Q1 net loss of $29.3 million, with cash reserves of $36.2 million, expected to fund operations until Q4 2025.Shares of Biomea have fallen 54.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves

Biomea Fusion is realigning its focus on diabetes and obesity programs, cutting 35% of its workforce and consolidating operations to reduce costs. 

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMEA News

BMEABiomea Fusion Inc